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PERSISTENCE AND COMPLIANCE WITH BISPHOSPHONATE
THERAPY AMONG POST-MENOPAUSAL OSTEOPOROTIC
WOMEN
Cramer J1,Amonkar MM2, Hebborn A3, Suppapanya N2
1Yale University, West Haven, CT, USA; 2GlaxoSmithKline, Collegeville,
PA, USA; 3Hoffmann-La Roche, Nutley, NJ, USA
OBJECTIVES: To compare persistence and compliance of
weekly and daily bisphosphonate regimens among post-
menopausal osteoporotic women. METHODS: Post-
menopausal osteoporotic women (>45 years) prescribed a
once-weekly (QW) bisphosphonate (alendronate 35 or 70mg) or
once-daily (QD) bisphosphonate (alendronate 5 or 10mg or rise-
dronate 5mg) were identiﬁed from an administrative claims
database comprising 30 health plans. The QW and QD study
cohorts were followed for 12 months after the index prescrip-
tion. Medication possession ratio (MPR) was used to estimate
compliance while persistence was calculated as the number of
days from the initial prescription to a lapse of >30 days after
completion of the previous reﬁll. RESULTS: Between 1997 and
2002, a total of 2741 post-menopausal osteoporotic women who
were prescribed a bisphosphonate (alendronate QW = 731; alen-
dronate or risedronate QD = 2010) were identiﬁed (mean age =
63.7 years). Average MPR for the combined study cohorts was
60.6%. However, QW users had a signiﬁcantly higher MPR than
QD users (69.2% QW vs 57.6% QD, t = -7.51 p < 0.0001).
Treatment persistence was signiﬁcantly longer among the QW
users than QD users (227 vs 185 days to discontinuation, respec-
tively, log rank, p < 0.0001). Also, approximately 44% of weekly
bisphosphonate users and 32% of daily bisphosphonate users
persisted with their therapy at the end of 12 months. CON-
CLUSIONS: Post-menopausal women prescribed a weekly 
bisphosphonate regimen had signiﬁcantly higher rates of com-
pliance and longer persistence compared with those taking a
more frequent, daily dosing regimen. However, rates for both
regimens were less than desirable. These data demonstrate that
less frequent dosing increases persistency, which is needed to
obtain maximal long-term therapeutic beneﬁts.
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PERSISTENCE WITH BISPHOSPHONATE THERAPY AND THE
IMPACT OF DOSING FREQUENCY IN PATIENTS WITH POST-
MENOPAUSAL OSTEOPOROSIS
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OBJECTIVES: The aim of this study was to compare the per-
sistence of use of daily and weekly administered bisphospho-
nates. METHODS: Data were obtained from the PHARMO
database, which includes linked drug-dispensing records and
hospital records of more than one million subjects in deﬁned
areas in The Netherlands. New female users of alendronate,
etidronate or risedronate aged 55 years and older in the period
January, 2000–September, 2003, were included in the study
cohort. One-year persistence of treatment was determined by
using episodes of bisphosphonate treatment based on the method
of Catalan. The effect of the dosing regimen and other determi-
nants including age, co-medication and fractures, on persistence
was assessed. RESULTS: The study cohort included 2124 new
users of bisphosphonates. Overall, 1-year persistence of bispho-
sphonates was low; only 911 (43%) users were persistent.
Etidronate users were less persistent (30%) than alendronate 
and risedronate users (46% and 42%, respectively). Among 
alendronate users, patients on the weekly regimen were more
persistent (52%) than those on the daily regimen (35%). A mul-
tivariate analysis including age, co-medication and fractures,
showed that patients using alendronate weekly were 2.26 times
more likely to be persistent (95%CI 1.66–3.09) compared to
patients using alendronate daily. CONCLUSIONS: Our results
indicate that persistence of bisphosphonate use is higher with a
less frequent dosing regimen. The improved persistence of the
weekly administered alendronate may theoretically be explained
by a reduced frequency to experience drug-related acute adverse
effects. However, persistence for both regimens can be con-
sidered to be suboptimal and leaves room for improvement.
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OBJECTIVES: To assess the prevalence and incidence of osteo-
porosis, determine recent and predict future time trends in the
Dutch population in the period 1993–2015. METHODS: Data
were obtained from the PHARMO database, which includes
linked drug-dispensing records and hospital records of more than
865,000 subjects in deﬁned areas in The Netherlands. Patients
(>45 years) who were hospitalised for osteoporosis (ICD9-CM:
733) or osteoporotic fractures (ICD-9-CM: 820, 812.0, 813.4,
805.2 and 805.4) and treated with glucocorticoids or anti-osteo-
porosis drugs (bisphosphonates, vitamin D, calcium, ralixofen,
HRT) between 1993 and 2002 were included. Prevalence of
osteoporosis was calculated as the total number of patients
having osteoporosis on a single ﬁxed day in a year (ﬁrst Wednes-
day of October). Incidence of osteoporosis was computed as the
number of new cases that met the inclusion criteria in a certain
year divided by total person-time contributed by the population
at risk. RESULTS: A total of 32,219 patients were included in
this cohort. Prevalence of osteoporosis increased from 36 in
1994 to 56 in 2002 per 1000 inhabitants. Incidence declined 
in the same period from 8.7 to 7.0 (per 1000 inhabitants.).
Extrapolations based on demographic changes in the future indi-
cate that prevalence of osteoporosis will increase up to more than
65 (per 1000 inhabitants) in 2015. CONCLUSIONS: Prevalence
of osteoporosis has been continuously increasing over the past
decade. Our data show that the pace of this increase slowly
declines probably due to increased awareness and screening that
leads to a decrease in the size of the ‘pool’ of undetected osteo-
porotic patients. Ageing of the population is becoming the pre-
dominant contributor to a further increase of the osteoporosis
prevalence in the future causing great social and economic
burden to the society. Prevention of osteoporosis and its conse-
quences is critical to reducing this burden.
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THE UNDER TREATMENT OF DEPRESSION IN CHRONIC PAIN
Sampson J, Marsh B
VA Medical Center, Gainesville, FL, USA
OBJECTIVES: Depression has been reported to be highly asso-
ciated with chronic pain. It is believed that chronic pain causes
